Nowe rodzaje szczepionek przeciwpasozytniczych

• Autorzy: Wedrychowicz H
• Języki publikacji: PL

Abstrakty

EN

The protection of humans and domestic animals against parasitic infections remains a major goal, especially in light of developing of drug resistant strains in many parasite species. "Classic" vaccines are based on attenuated infective stages of protozoan and helminth parasites. Although such vaccines are effective in confering host immunity against several Protozoan (coccidiosis, giardiosis, toxoplasmosis) diseases and one helminth (dictyocaulosis) they are very unstable and expensive. Recombinant techniques enable to obtain protective antigens quickly and in considerable quantities, cultivating of the bacteria and purification of the recombinant protein is less expensive than the maintenance of host animals and isolation of the protective antigens from harvested parasites. Moreover, the cloned protective antigens may be deprived of epitopes responsible for immunopathology. However, at present only one anti-parasite recombinant protein vaccine is commercially available (TickGARD). Such a situation may result from that many protective parasitic antigens cannot be expressed in bacteria or yeast in anative from. DNA vaccines present many advantages over protein ones. Firstly, the antigenic proteins synthesised within the host cell possess an appropriate molecular structure and undergo a posttranslational modifications specific for a native protein. The next advantage of DNA vaccines is that DNA is easier to handle and more resistant than proteins to temperature changes. DNA vaccines are likely to induce novel mechanisms of i mm une response, which may be beneficial in case of parasitic invasions. Costs of DNA vaccines are comparable, and may be even lower, in comparison to recombinant protein vaccines. The main obstacle preventing the use of DNA vaccines is still Jack of the complete knowledge conceming mechanisms of their action. Vaccines based on transgenic plants (=edible vaccines), expressing the protective parasitic antigens, present another promising approach in research on anti-parasitic vaccines. Such vaccines may be of special importance in prevention of infections with gastrointestinal parasites.

Słowa kluczowe

PL

parazytologia; szczepionki przeciwpasozytnicze

• Wydawca: -
• Czasopismo: Wiadomości Parazytologiczne
• Rocznik: 2000
• Tom: 46
• Numer: 1
• Opis fizyczny: s.21-27,bibliogr.

Twórcy

autor

Wedrychowicz H

• Szkola Glowna Gospodarstwa Wiejskiego, Grochowska 272, 03-849 Warszawa

Bibliografia

• ALONSO P. L., DGEDGE M. 1999. A new impetus for malaria research and control. Parasitol. Today 15: 48-49.
• CARMONA C., Down A. J., SMITH A. M., DALTON J. P. 1993. Cathepsin L proteinase secreted by Fasciola hepatica in vitro prevents antibody-mediated eosinophil attachment to newly excysted juveniles. Mol. Biochem. Parasitol. 62: 9-18.
• CREANEY J., WILSON L., DOSEN M., SANDEMAN R. M., SPITHILL T. W., PARSONS J. C.1996. Fasciola hepatica: Irradiation-induced alterations in carbohydrate nad cathepsin-B protease expression in newly excysted juvenile liver fluke. Exp. Parasitol. 83: 202-15.
• EMERY D. L. 1996. Vaccination against worm parasites of animals. Vet. Parasitol. 64: 31-45.
• ERTLH.C. J., XIANG Z.1996. Novel vaccine approaches. J. Immunol. 156: 3579-3582.
• FYNAN E., WEBSTER R. G., FULLER D. H., HAYNES J. R., SANTORO J. C., ROBINSON H. L. 1993. DNA vaccines: Protective immunizations by parenteral, mucosal and gene-gun inoculations. Proc. Natl. Acad. Sci. U.S.A 90: 11478-11482.
• GEARY T. G., SANGSTER N. C., THOMPSON D. P. 1999. Frontiers in anthelmintic pharmacology. Vet. Parasitol. 84: 275-295.
• HEATH D. D., HOLCMAN B. 1997. Vaccinations against Echinococcus in perspective. Acta Tropica 67: 37-41.
• HEUSSLER V. T., DOBBELAERE D. A. E. 1994. Cloning of a protease gene family of Fasciola hepatica by the polymerase chain reaction. Mol. Biochem. Parasitol. 64: 11-23.
• HOFFMAN S. L., SEDEGAH M., HEDSTROM R. C. 1994. Protection against malaria by immunization with a Plasmodium yoelli circumsporozoite protein nucleic acid vaccine. Vaccine 12: 1529-1533.
• 1998. Phase I malaria DNA vaccine trial yields first data in man. DNA VaccineWeb, Internet, Materials of the Third National Symposium on Basic Aspects of Vaccines.
• KOFTA W., WĘDRYCHOWICZ H. 1999. Ocena reakcji obronnej szczurów immunizowanych cDNA proteinazy cysteinowej Fasciola hepatica na zarażenie tą przywrą. Mat. Konferencji: "Zastosowane technik molekularnych w parazytologii", Gdynia, 7- 8 maja 1999, 21.
• KOTOMSKI G. 1999. Izolacja i charakterystyka produktów ekskrecyjno-sekrecyjnych larw i osobników dorosłych Unciaria stenocephala oraz określenie ich roli w indukowaniu odporności na inwazję. Rozprawa doktorska, Wydział Wet. SGGW, Warszawa.
• LOFTHOUSE S. A. 1996. Cytokines as adjuvants for ruminant vaccines. Int. J. Parasitol. 26: 835- 842.
• MASON H. S., ARNTZEN C. J. 1995. Transgenic plants as vaccine production systems. Trends in Biotechnol. 13: 388-392.
• MEEUSEN E. N. T. 1998. Differential migration of TH1 and Th2 cells - implications for vaccine and infection studies. Vet. Immunol. Immunopath. 63: 157-166.
• MILLER T. A. 1978. Industrial development and field use od canine hookworm vaccine. Adv. Parasitol. 17: 315-384.
• MOR T. S. 1998. Perspective: edible vaccines - a concept coming of age. Trends in Microbiol. 6: 449-453.
• MUNN E. A. 1997. Rational design of nematode vaccines: hidden antigens. Int. J. Parasitol. 27, 359-366.
• OLSON M. E. 1999. Giardiasis and the use of vaccination to control infection. In: A new millenium in parasite control; Fort Dodge, Copenhagen, August 1999.
• SPITHILL T. W., DALTON J. P. 1998. Progress in development of liver fluke vaccines. Parasitol. Today 14: 224-228.
• RICKARD M. D. 1995. Taenia avis recombinant vaccine - 'quo vadit'. Parasitology 110: S5-S9.
• WĘDRYCHOWICZ H., KLOCKIEWICZ M. 1994. Protective and diagnostic molecules of Fasciola hepatica. Acta Parasitol. 39: 173-178.
• - 1995. Secretory IgA in gastrointestinal parasitic infections. Acta Parasitol. 40: 1-11.
• - 1996a. Występowanie, mechanizmy i metody wykrywania lekooporności nicieni żołądkowo-jelitowych owiec i kóz. Lek w Polsce (Weterynaria) 13: 2-13.
• - 1996b. Występowanie oraz mechanizmy lekooporności przywr i nicieni pasożytujących u zwierząt roślinożernych. Med. Wet. 52: 494-498.
• WUFFELS G., SALVATORE L., DOSEN M., WADDINGT0N J. et al. 1994. Vaccination of sheep with purifiedcysteine proteinases of Fasciola hepatica decreases worm fecundity. Exp. Parasitol. 78: 132-148.
• WILSON L. R., GOOD R. T., PANACCIO M., WIJFFELS G. L., SANDEMAN R. M., SPITHILL T. W. 1998. Fasciola hepatica: characterization and cloning of the major cathepsin B-protease secreted by newly excystedjuvenile liver fluke. Exp. Parasitol. 88: 85-94.
• WILLADSEN P. 1997. Novel vaccines for ectoparasites. Vet. Parasitol. 71: 209-222.
• WYNN A. T., CHEEVER A. W., JANKOVIC D., POINDEXTER R. W., CASPAR P., LEWIS F. A., SHER 1995. An IL-12 - based vaccination method for prevnting fibrosis induced by schistosome infection. Nature 376: 594-596.
• Xu D., LIEW F.Y. 1994. Genetic vaccination against leishmaniasis. Vaccine 112: 1534-1536.
• - - 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84: 173-176.
• YANG W., WAINE G. J., MCMANUS D. P. 1995. Antibodies to Schistosoma japonicum (asian blood fluke) paramyosin induced by nucleic acid vaccination. Biochem. Biophys. Res. Commun. 212: 1029-1039.